Ocular pharmacokinetics and safety of ciclosporin, a novel topical treatment for dry eye

Clinical Pharmacokinetics

Volumn 44, Issue 3, 2005, Pages 247-261

  Tang Liu, Diane D S ^a   Acheampong, Andrew ^a  

^a ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; COLCHICINE; CREATININE; CYCLOSPORIN A; OPTIMMUNE; PLACEBO; PREDNISOLONE;

AMINOTRANSFERASE BLOOD LEVEL; BURNING SENSATION; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DNA SYNTHESIS; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG PENETRATION; DRUG SAFETY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TISSUE LEVEL; DRY EYE; EMULSION; EYE DISEASE; HUMAN; HYPERTENSION; IMMUNOMODULATION; IN VITRO STUDY; KIDNEY DISEASE; LIVER TOXICITY; MULTIPLE DRUG DOSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE;

ANIMALS; CHEMISTRY, PHYSICAL; CYCLOSPORINE; DRY EYE SYNDROMES; EYE; HUMANS; IMMUNOSUPPRESSIVE AGENTS;

EID: 16444380147     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200544030-00003     Document Type: Review

References (87)

1. Faulds D, Goa KL, Benfield P. Cyclosporin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs 1993; 45: 953-1040
2. DeBakey ME. Cyclosporin A: a new era in organ transplantation. Compr Ther 1984; 10: 7-15
3. Nussenblatt RB, Palestine AG, Chan CC, et al. Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. Am J Ophthalmol 1991; 112: 138-46
4. Dick AD, Azim M, Forrester JV. Immunosuppressive therapy for chronic uveitis: optimising therapy with steroids and Cyclosporin A. Br J Ophthalmol 1997; 81: 1107-12
5. Ozdal PC, Ortac S, Taskintuna I, et al. Long-term therapy with low dose cyclosporin A in ocular Behcet's disease. Doc Ophthalmol 2002; 105: 301-12
6. Masuda K, Nakajima A, Urayama A, et al. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet's disease. Lancet 1989; 1: 1093-6
7. Le Hoang P, Girard B, Deray G, et al. Cyclosporine in the treatment of birdshot retinochoroidopathy. Transplant Proc 1988; 20: 128-30
8. Binder AI, Graham EM, Sanders MD, et al. Cyclosporin A in the treatment of severe Behcet's uveitis. Br J Rheumatol 1987; 26: 285-91
9. Oh C, Apel AJ, Saville BA, et al. Local efficacy of cyclosporine in corneal transplant therapy. Curr Eye Res 1994; 13: 337-43
10. BenEzra D, Matamoros N, Cohen E. Treatment of severe vernal keratoconjunctivitis with cyclosporine A eyedrops. Transplant Proc 1988; 20: 644-9
11. Calonge M. The treatment of dry eye. Surv Ophthalmol 2001; 45 Suppl. 2: S227-39
12. Kiang E, Tesavibul N, Yee R, et al. The use of topical cyclosporin A in ocular graft-versus-host-disease. Bone Marrow Transplant 1998; 22: 147-51
13. Diaz-Valle D, Benitez del Castillo JM, Castillo A, et al. Immunologic and clinical evaluation of postsurgical necrotizing sclerocorneal ulceration. Cornea 1998; 17: 371-5
14. Gunduz K, Ozdemir O. Topical cyclosporin as an adjunct to topical acyclovir treatment in herpetic stromal keratitis. Ophthalmic Res 1997; 29: 405-8
15. Sail K, Stevenson OD, Mundorf TK, et al. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology 2000; 107: 631-9
16. Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. Ophthalmology 2000; 107: 967-74
17. Stern ME, Geo J, Siemasko KF, et al. Role of the lacrimal gland functional unit in the pathophysiology of dry eye. Exp Eye Res 2004; 78: 409-16
18. Pepose JS, Akata RF, Pflugfelder SC, et al. Mononuclear cell phenotypes and immunoglobulin gene rearrangements in lacrimal gland biopsies from patients with Sjogren's syndrome. Ophthalmology 1990; 97: 1599-605
19. Pflugfelder SC, Wilhelmus KR, Osato MS, et al. The autoimmune nature of aqueous tear deficiency. Ophthalmology 1986; 93: 1513-7
20. Borel JF, Baumann G, Chapman I, et al. In vivo pharmacological effects of ciclosporin and some analogues. Adv Pharmacol 1996; 35: 115-246
21. Drosos AA, Skopouli FN, Costopoulos JS, et al. Cyclosporin A (CyA) in primary Sjogren's syndrome: a double blind study. Ann Rheum Dis 1986; 45: 732-5
22. Laibovitz RA, Solch S, Andriano K, et al. Pilot trial of cyclosporine 1% ophthalmic ointment in the treatment of keratoconjunctivitis sicca. Cornea 1993; 12: 315-23
23. Power WJ, Mullaney P, Farrell M, et al. Effect of topical cyclosporin A on conjunctival T cells in patients with secondary Sjogren's syndrome. Cornea 1993; 12: 507-11
24. Fox RI, Tornwall J, Maruyama T, et al. Evolving concepts of diagnosis, pathogenesis, and therapy of Sjogren's syndrome. Curr Opin Rheumatol 1998; 10: 446-56
25. Kaswan RL, Salisbury MA, Ward DA. Spontaneous canine keratoconjunctivitis sicca: a useful model for human keratoconjunctivitis sicca: treatment with cyclosporine eye drops. Arch Ophthalmol 1989; 107: 1210-6
26. Kaswan RL, Salisbury MA. A new perspective on canine keratoconjunctivitis sicca: treatment with ophthalmic cyclosporine. Vet Clin North Am Small Anim Pract 1990; 20: 583-613
27. Morgan RV, Abrams KL. Topical administration of cyclosporine for treatment of keratoconjunctivitis sicca in dogs. J Am Vet Med Assoc 1991; 199: 1043-6
28. Olivero DK, Davidson MG, English RV, et al. Clinical evaluation of 1% cyclosporine for topical treatment of keratoconjunctivitis sicca in dogs. J Am Vet Med Assoc 1991; 199: 1039-42
29. Wiederholt M, Kossendrup D, Schulz W, et al. Pharmacokinetic of topical cyclosporin A in the rabbit eye. Invest Ophthalmol Vis Sci 1986; 27: 519-24
30. Kanai A, Alba RM, Takano T, et al. The effect on the cornea of alpha cyclodextrin vehicle for cyclosporin eye drops. Transplant Proc 1989; 21: 3150-32
31. Reidy JJ, Gebhardt BM, Kaufman HE. The collagen shield: a new vehicle for delivery of cyclosporin A to the eye. Cornea 1990; 9: 196-9
32. Calvo P, Sanchez A, Martinez J, et al. Polyester nanocapsules as new topical ocular delivery systems for cyclosporin A. Pharm Res 1996; 13: 311-5
33. De Campos AM, Sanchez A, Alonso MJ. Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface: application to cyclosporin A. Int J Pharm 2001; 224: 159-68
34. Gebhardt BM, Kaufman HE. Collagen as a delivery system for hydrophobic drugs: studies with cyclosporine. J Ocul Pharmacol Ther 1995; 11: 319-27
35. Borel JF. CsA: historical perspectives. Transplant Proc 1983; 15: 2219-29
36. Secchi AG, Tognon MS, Leonardi A. Topical use of cyclosporine in the treatment of vernal keratoconjunctivitis. Am J Ophthalmol 1990; 110: 641-5
37. Bonduelle S, Foucher C, Leroux JC, et al. Association of cyclosporin to isohexylcyanoacrylate nanospheres and subsequent release in human plasma in vitro. J Microencapsul 1992; 9: 173-82
38. Bonduelle S, Carrier M, Pimienta C, et al. Tissue concentration of nanoencapsulated radio-labelled cyclosporin following peroral delivery in mice or ophthalmic application to rabbits. Eur J Pharm Biopharm 1996; 42: 313-9
39. Belin MW, Bouchard CS, Frantz S, et al. Topical cyclosporine in high-risk corneal transplants. Ophthalmology 1989; 96: 1144-50
40. Restasis™ prescribing information. Irvine (CA): Allergan Inc., 2003
41. Acheampong AA, Shackleton M, Tang-Liu D, et al. Distribution of cyclosporin A in ocular tissues after topical administration to albino rabbits and beagle dogs. Curr Eye Res 1999; 18: 91-103
42. Snibson GR, Greaves JL, Soper ND, et al. Precorneal residence times of sodium hyaluronate solutions studied by quantitative gamma scintigraphy. Eye 1990; 4 (Pt 4): 594-602
43. Bethem R, Lehman J, Woolley P, et al. Quantitative analysis of cyclosporin A in human whole blood by LC-API/MS/MS. Pharm Res 1999; 14: S-698
44. Kirchner GI, Vidal C, Winkler M, et al. LC/ESI-MS allows simultaneous and specific quantification of SDZ RAD and cyclosporine, including groups of their metabolites in human blood. Ther Drug Monit 1999; 21: 116-22
45. Schroeder TJ, Brunson ME, Pesce AJ, et al. A comparison of the clinical utility of the radioimmunoassay, high-performance liquid chromatography, and TDx cyclosporine assays in outpatient renal transplant recipients. Transplantation 1989; 47: 262-6
46. Simpson J, Zhang Q, Ozaeta P, et al. A specific method for the measurement of cyclosporin A in human whole blood by liquid chromatography- tandem mass spectrometry. Ther Drug Monit 1998; 20: 294-300
47. Steimer W. Performance and specificity of monoclonal immunoassays for cyclosporine monitoring: how specific is specific? Clin Chem 1999; 45: 371-81
48. Zucchelli GC, Pilo A, Chiesa MR, et al. Progress report of an external quality assessment scheme for cyclosporine assay. Ther Drug Monit 1996; 18: 273-9
49. Kaswan RL. Intraocular penetration of topically applied cyclosporine. Transplant Proc 1988; 20: 650-5
50. Mosteller MW, Gebhardt BM, Hamilton AM, et al. Penetration of topical cyclosporine into the rabbit cornea, aqueous humor, and serum. Arch Ophthalmol 1985; 103: 101-2
51. Bellot JL, Alio JL, Ruiz Moreno JM, et al. Corneal concentration and systemic absorption of cyclosporin-A following its topical application in the rabbit eye. Ophthalmic Res 1992; 24: 351-6
52. BenEzra D, Maftzir G. Ocular penetration of cyclosporin A: the rabbit eye. Invest Ophthalmol Vis Sci 1990; 31: 1362-6
53. Foets B, Missotten L, Vanderveeren P, et al. Prolonged survival of allogeneic corneal grafts in rabbits treated with topically applied cyclosporin A: systemic absorption and local immunosuppressive effect. Br J Ophthalmol 1985; 69: 600-3
54. Study report PK-98-074. Ocular cyclosporine distribution during 91/2 days of dosing of 0.05% and 0.1% 3H-cyclosporin A emulsion to albino rabbit eyes. Irvine (CA): Allergan, 1998. (Data on file)
55. Study report PK-99-073. Cornea, conjunctiva and aqueous humor concentrations in rabbits and dogs dosed every 15 minutes four times with an aqueous formulation of 0.5% 3H-cyclosporine. Irvine (CA): Allergan, 1999. (Data on file)
56. Study report PK-98-016. Ocular absorption and disposition in beagle dogs following multiple ocular doses of 0.2% 3H-cyclosporine emulsion. Irvine (CA): Allergan, 1996. (Data on file)
57. Acheampong AA, Shackleton M, Lam S, et al. Cyclosporine distribution into the conjunctiva, cornea, lacrimal gland, and systemic blood following topical dosing of cyclosporine to rabbit, dog, and human eyes. Adv Exp Med Biol 1998; 438: 1001-4
58. Study report PK-96-011. Dose proportionality of ocular tissue 3H-cyclosporine concentrations after a single dose administration of 0.05%, 0.2% and 0.4% cyclosporine emulsions into rabbit eyes. Irvine (CA): Allergan, 1996. (Data on file)
59. Theng J, Zhiou L, Tan D, et al. Distribution of cyclosporine A in the cornea after topical or oral administration. J Ocular Pharmacol Ther 2002; 18: 83-8
60. Althaus C, Dagres E, Reinhard T, et al. Cyclosporin-A and its metabolites in the anterior chamber after topical and systemic application as determined with high-performance liquid chromatography-electrospray mass spectrometry. Ger J Ophthalmol 1996; 5: 189-94
61. Perry HD, Donnenfeld ED, Acheampong A, et al. Topical cyclosporine A in the management of postkeratoplasty glaucoma and corticosteroid-induced ocular hypertension (CI-OH) and the penetration of topical 0.5% cyclosporine A into the cornea and anterior chamber. CLAO J 1998; 24: 159-65
62. Pfau B, Kruse FE, Rohrschneider K, et al. Comparison between local and systemic administration of cyclosporin A on the effective level in conjunctiva, aqueous humor and serum [in German]. Ophthalmologe 1995; 92: 833-9
63. Chipont E, Diaz-Llopis M, Tomas S, et al. Collagen shields and intraocular penetration of cyclosporin. Arch Soc Esp Oftalmol 1995; 69: 251-7
64. Diaz-Llopis M, Menezo JL. Penetration of 2% cyclosporin eyedrops into human aqueous humour. Br J Ophthalmol 1989; 73: 600-3
65. Minguez E, Tiestos MT, Cristobal JA, et al. Intraocular absorption of cyclosporin A eyedrops [in French]. J Fr Ophtalmol 1992; 15: 263-7
66. Vickers AE, Fischer V, Connors S, et al. Cyclosporin A metabolism in human liver, kidney, and intestine slices: comparison to rat and dog slices and human cell lines. Drug Metab Dispos 1992; 20: 802-9
67. Combalbert J, Fabre I, Fabre G, et al. Metabolism of cyclosporin A: IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. Drug Metab Dispos 1989; 17: 197-207
68. Madhu C, Dinh D, Babusis D, et al. Expression of cytochrome P450 isoenzymes in dog and human eye. Proceedings of the 9th Annual North American ISSX Meeting; 1999 Oct 24-28; Nashville. Bethesda (MD): ISSX 1999; 15: 162
69. Sandborn WJ, Lawson GM, Krom RA, et al. Hepatic allograft cyclosporine concentration is independent of the route of cyclosporine administration and correlates with the occurrence of early cellular rejection. Hepatology 1992; 15: 1086-91
70. Hanas E, Tufveson G, Lindgren PG, et al. Concentration of cyclosporin-A and its metabolites in transplanted human kidney tissue during rejection and stable graft function. Clin Transplant 1991; 5: 107-11
71. Sandborn WJ, Tremaine WJ, Lawson GM. Clinical response does not correlate with intestinal or blood cyclosporine concentrations in patients with Crohn's disease treated with high-dose oral cyclosporine. Am J Gastroenterol 1996; 91: 37-43
72. Sandborn WJ, Tremaine WJ, Schroeder KW, et al. Cyclosporine enemas for treatment-resistant, mildly to moderately active, left-sided ulcerative colitis. Am J Gastroenterol 1993; 88: 640-5
73. Physician's desk reference. Montvale (NJ): Medical Economics, 2002: 2388-91
74. Singh G, Lindstrom RL, Doughman DJ. Cyclosporin A on human corneal endothelium. Cornea 1984; 3: 272-7
75. BenEzra D, Antebe I, Maftzir G. Differential effect of cyclosporin A on lymphocyte and keratocyte proliferation [abstract]. Invest Ophthalmol Vis Sci 1987; 28: 42
76. Angelov O, Wiese A, Yuan Y, et al. Preclinical safety studies of cyclosporine ophthalmic emulsion. Adv Exp Med Biol 1998; 438: 991-5
77. Salisbury MA, Kaswan RL, Brown J. Effect of topical cyclosporine on the recovery of micro-organisms from dogs with KCS [abstract]. Invest Ophthalmol Vis Sci 1994; 35: 1693
78. Ryffel B. The carcinogenicity of ciclosporin. Toxicology 1992; 73: 1-22
79. Donatsch P, Ryffel B. Pharmacokinetics of cyclosporine in toxicological studies. Transplant Proc 1986; 6: 71-6
80. Study report PK-00-013. Cyclosporine A concentrations in the eyes of rats and dogs dosed orally with cyclosporin A for 5 days. Irvine (CA): Allergan, 2000. (Data on file)
81. de Vries J, Baarsma GS, Zaal MJ, et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. Br J Ophthalmol 1990; 74: 344-9
82. Cohen E, Raz J, Maftzir G, et al. Low-dose cyclosporin A in uveitis. Ocul Immunol Inflamm 1993; 1: 195-201
83. Towler HM, Lightman SL, Forrester JV. Low-dose cyclosporin therapy of ocular inflammation: preliminary report of a long-term follow-up study. J Autoimmun 1992; 5 Suppl. A: 259-64
84. Towler HM, Whiting PH, Forrester JV. Combination low dose cyclosporin A and steroid therapy in chronic intraocular inflammation. Eye 1990; 4 (Pt 3): 514-20
85. Towler HM, Cliffe AM, Whiting PH, et al. Low dose cyclosporin A therapy in chronic posterior uveitis. Eye 1989; 3 (Pt 3): 282-7
86. Nussenblatt RB, Palestine AG, Chan CC. Cyclosporine therapy for uveitis: long-term followup. J Ocul Pharmacol 1985; 1: 369-82
87. Small DS, Acheampong A, Reis B, et al. Blood concentrations of cyclosporin a during long-term treatment with cyclosporin a ophthalmic emulsions in patients with moderate to severe dry eye disease. J Ocul Pharmacol Ther 2002; 18: 411-8